Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

We hypothesized that bortezomib, an agent that suppresses HIF-1α transcriptional activity, when combined with bevacizumab, would obviate the HIF-1α resistance pathway. The objectives of this phase I trial were to assess safety and biological activity of this combination. Patients with advanced, refr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2014-11, Vol.5 (21), p.10280-10292
Hauptverfasser:	Falchook, Gerald S, Wheler, Jennifer J, Naing, Aung, Jackson, Edward F, Janku, Filip, Hong, David, Ng, Chaan S, Tannir, Nizar M, Lawhorn, Kristie N, Huang, Mei, Angelo, Laura S, Vishwamitra, Deeksha, Hess, Kenneth, Howard, Adrienne N, Parkhurst, Kristin L, Amin, Hesham M, Kurzrock, Razelle
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Boronic Acids - administration & dosage Boronic Acids - adverse effects Bortezomib Breast Neoplasms - drug therapy Carcinoma, Renal Cell - drug therapy Clinical Research Paper Fatigue - etiology Female Humans Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors Hypoxia-Inducible Factor 1, alpha Subunit - genetics Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Kidney Neoplasms - drug therapy Magnetic Resonance Imaging Male Middle Aged Neoplasm Staging Neovascularization, Pathologic - drug therapy Proteasome Endopeptidase Complex - drug effects Pyrazines - administration & dosage Pyrazines - adverse effects Thrombocytopenia - etiology Treatment Outcome Vascular Endothelial Growth Factor A - immunology Vascular Endothelial Growth Factor A - metabolism Vascular Endothelial Growth Factor Receptor-2 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!